Myeloperoxidase Antikörper
Kurzübersicht für Myeloperoxidase Antikörper (ABIN2475782)
Target
Alle Myeloperoxidase (MPO) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
- 
    - 
                                            Produktmerkmale
- Purified IgG
- 
                                            Aufreinigung
- Purified
- 
                                            Isotyp
- IgG1
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1.0 mg/mL
 
- 
                                            
- 
    - 
                                            : "Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease."    in: The Journal of allergy and clinical immunology, Vol. 122, Issue 5, pp. 961-8, (2008)         (PubMed).        
 : "Difference in antigenic determinant profiles between human and rat myeloperoxidase." in: Clinical and experimental immunology, Vol. 132, Issue 3, pp. 505-8, (2003) (PubMed).
 
 
- 
                                            : "Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease."    in: The Journal of allergy and clinical immunology, Vol. 122, Issue 5, pp. 961-8, (2008)         (PubMed).        
- 
    - Myeloperoxidase (MPO)
- 
                                            Andere Bezeichnung
- MYELOPEROXIDASE
- 
                                            Gen-ID
- 4353
- 
                                            UniProt
- P05164
- 
                                            Pathways
- Chromatin Binding
 Target
- 
                    
 
                                     
                                     
                                    